Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
By S. Hadziyannis, H. Sette, T. Morgan, V. Balan, M. Diago, P. Marcellin, G. Ramadori, H. Bodenheimer, D. Bernstein, M. Rizzetto and 4 more. Annals of Internal Medicine, 2004
2,999 citations recorded by the source corpus.
Subfields: Epidemiology, Hepatology
View Paper: https://www.semanticscholar.org/paper/780ebc7426ebe6ab02f822046a093aba796ecf3f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Hepatology
Citations in the corpus
- Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. (2004, background): “HCV infection Estimated duration of infection, median (range), y 16 (2-30) 17 (3-33) .”
- Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus (2015, result): “Persons coinfected with HIV/HCV also had lower responses to PEG-IFN and RBV than those with HCV infection alone, an observation largely explained by the higher baseline HCV RNA levels.(113,114) However, with the advent of DAAs, differences in treatment responses between monoand coinfected patients h”
- EASL Recommendations on Treatment of Hepatitis C 2018. (2018, neutral): “5 g/dl [39-47].”
- Interferon signaling and treatment outcome in chronic hepatitis C (2008, background): “Our finding that the frequency and degree of preactivation of the endogenous IFN system depend on the HCV GT could provide an explanation for the observation that GT 2 and 3 infections can be cured in 80% of patients, compared with 50% of infections with GT 1 (4).”